Significance of inducible nitric oxide synthase expression in benign and malignant breast epithelium: an immunohistochemical study of 151 cases

Significance of inducible nitric oxide synthase expression in benign and malignant breast epithelium: an immunohistochemical study of 151 cases
复制标题

DOI:
10.1007/s00428-005-1250-2
复制
发表时间:
2005-07-01
期刊:
影响因子:
3.5
通讯作者:
Dincol, D
Dincol, D
中科院分区:
医学3区
文献类型:
--
作者:
Bulut, A;Erden, E;Dincol, D

文献摘要

被引文献

相似文献

钙依赖性诱导型一氧化氮合酶 (iNOS) 在乳腺癌中的作用存在争议,并且 iNOS 表达对预后的影响尚不清楚。在本研究中,我们旨在探讨免疫组织化学 iNOS 表达在 100 例浸润性导管癌中的意义。此外,还包括11例正常乳腺组织、20例普通导管增生(UDH)和20例纤维腺瘤。我们发现 78% 的恶性病例和 75% 的良性病例表现出 iNOS 免疫反应性。然而,与良性乳房相比,癌症组中iNOS表达的强度和数量显着较高(P < 0.001),表明iNOS在乳腺癌发生中发挥作用。我们无法显示 iNOS 表达与肿瘤分级、腋窝淋巴结状态和雌激素受体表达之间的相关性。在随访5-12年的50例腋窝阴性病例中,iNOS表达强的病例无病生存率(DFS)显着较低(P=0.05)。由于强 iNOS 表达与短 DFS 相关,因此我们得出结论,需要进一步研究来阐明 iNOS 表达是否可能是乳腺癌中有用的预后标志物,特别是在腋窝阴性组中。
The role of calcium independent inducible nitric oxide synthase (iNOS) in breast carcinoma is controversial, and the implications of iNOS expression on prognosis are not known. In this study, we aimed to investigate the significance of immunohistochemical iNOS expression in 100 invasive ductal carcinomas. In addition, 11 normal breast tissues, 20 cases of usual ductal hyperplasias (UDHs) and 20 fibroadenomas were included. We found that 78% of malignant and 75% of benign cases showed iNOS immunoreactivity. However, the intensity and the quantity of iNOS expression were significantly higher in the cancer group when compared with benign breasts (P < 0.001), suggesting a role of iNOS in breast carcinogenesis. We were unable to show a correlation between iNOS expression and tumor grade, axillary lymph node status, and estrogen receptor expression. In 50 axilla negative cases having 5-12 years follow-up, disease free survival (DFS) rate was significantly lower in cases showing strong iNOS expression (P=0.05). As strong iNOS expression was correlated with short DFS, we concluded that further studies would be necessary to elucidate if iNOS expression might be a useful prognostic marker in breast carcinoma, especially in the axilla negative group.